Abstract: How prostate cancer is diagnosed and staged is an ever-evolving field. It plays a fundamental role in ensuring the appropriate therapeutic options are offered to the patient whilst preventing overdiagnosis and overtreatment. Despite the numerous advances in the field, a suspicion of prostate cancer continues to arise from digital rectal examination and measurement of serum prostate specific antigen (PSA). Additional derivatives of serum PSA along with urinary biomarkers and multiparametric magnetic resonance imaging can then help to risk stratify patients in order to appropriately counsel them on the risks and benefits of a prostate biopsy. After a diagnosis of prostate cancer is reached, further staging may be required and can be achieved by a variety of imaging techniques such as computed tomography (CT), bone scintigraphy, and prostate specific membrane antigen-based positron-emission tomography/CT. In this chapter, we review the current role of these and other diagnostic tools in prostate cancer.

Keywords: diagnosis; imaging; prostate biopsy; prostate cancer gene 3; prostate-specific antigen
INTRODUCTION

Diagnostic tools for prostate cancer have undergone significant advancements in recent years to improve the accuracy of prostate cancer detection and avoid over-diagnosis and subsequent overtreatment. Despite this, a suspicion of prostate cancer continues to arise from a raised serum prostate specific antigen (PSA) level, and/or a digital rectal examination (DRE). However, an elevated PSA alone should no longer necessitate a prostate biopsy. The use of diagnostic adjuncts can help to predict the presence of clinically significant prostate cancer thereby avoiding unnecessary biopsies in a proportion of patients.

DIGITAL RECTAL EXAMINATION (DRE)

DRE can be used as an inexpensive diagnostic tool to check the prostate for cancer and to give an assessment of the prostate volume. It has the ability to detect prostate cancer with a volume of >0.2ml, if situated in the posterior peripheral zone, and can be used to raise suspicion irrespective of PSA. However, there is a high degree of interobserver variability, and a normal DRE does not eliminate the risk of a significant prostate cancer (1). An historical prospective multicenter trial found 18% of prostate cancers were detected solely by DRE (2), nowadays this figure is thought to be less. Nevertheless, an abnormal DRE is an indication for a prostate biopsy irrespective of the PSA.

PROSTATE-SPECIFIC ANTIGEN (PSA)

PSA is, broadly speaking, an organ-specific glycoprotein secreted by the prostatic epithelium which may be elevated in a variety of conditions, both benign and malignant. Higher levels of PSA indicate a greater likelihood of prostate cancer. A PSA cut-off of ≤4ng/ml was originally proposed as a normal level in men aged 50–70 years. However, analysis of men with a PSA level of ≤4.0ng/ml in the Prostate Cancer Prevention Trial (PCPT) found 15% had clinically significant prostate cancer (3). Therefore, the ability to detect prostate cancer at any PSA level means that no cut-off thresholds for PSA can be used with absolute confidence. Furthermore, a single elevated PSA reading cannot be relied upon due to normal biological fluctuations. A population-based study found that 30% of men with an abnormal PSA had a return to normal PSA on their next reading (4). This highlights the importance of obtaining a confirmatory PSA reading a few weeks after the first reading. The unreliability of PSA means instead the urologist must take into consideration additional factors to determine if the patient should proceed to biopsy, which may include PSA derivatives.

Age-adjusted PSA

Serum PSA readings do not account for the normal age-related PSA changes. The Olmstead county population study demonstrated that serum PSA increases with
age and recommended age-specific reference ranges (Table 1) (5). Therefore, if the decision to proceed to further diagnostic tests for prostate cancer is being based solely on a PSA reading, the patient's age should be accounted for in order to appropriately counsel them and avoid an unnecessary biopsy.

**PSA density**

In addition to changes in PSA with age, the Olmstead county population study also demonstrated an increase in PSA with increasing prostate volume (5). To account for this, PSA density can be calculated as the total PSA divided by prostate volume. An increased PSA density is associated with a higher risk of prostate cancer, with a generally agreed cut off value of between 0.12–0.15 ng/ml/cc (6). A prospective multi-center study in patients undergoing an extended template biopsy has found PSA density to be more predictive than total PSA for detecting prostate cancer (7).

**PSA kinetics**

Changes in PSA over time can be assessed as PSA velocity (change in PSA over time, ng/ml/year) and PSA doubling time (number of months for the PSA to increase two-fold). Whilst PSA kinetics are useful for prognostic purposes after patients have received treatment, they currently have no role in the diagnostic setting (8).

**Free and total PSA**

Total PSA readings include the sum of all detectable forms of PSA, including PSA bound to protease inhibitors and free PSA. For reasons that are unclear, the percentage of free PSA has been demonstrated to be lower in patients with prostate cancer compared to those with benign disease (9). A multi-center prospective study evaluated men with a benign prostate gland on palpation and a total PSA level of 4 to 10 ng/ml. The study found the probability of prostate cancer in men aged 65 to 75 years was 55% when the free/total (f/t) PSA ratio was 0.1 and reduced to just 9% when the f/t PSA ratio was >0.25 (10). Therefore, in these select patients with a benign prostate gland and PSA of 4 to 10 ng/ml measuring

---

| Age (years) | Serum PSA reference range ng/ml |
|------------|--------------------------------|
| 40 – 49    | 0 – 2.5                        |
| 50 – 59    | 0 – 3.5                        |
| 60 – 69    | 0 – 4.5                        |
| 70 – 79    | 0 – 6.5                        |

---
free PSA may help to avoid unnecessary imaging or biopsy; but it should be used cautiously as it can be affected by other factors including prostate volume and most patients’ f/t PSA ratio falls between 0.1 and 0.25 (11).

**ADDITIONAL SERUM TESTS**

Additional assays are now commercially available measuring a panel of kallikreins. The use of these tests aims to reduce the number of unnecessary prostate biopsies.

**Prostate health index**

The prostate health index (Phi) test uses a formula to combine the results of total PSA, free PSA and [-2]proPSA ([-2]proPSA/free PSA x √tPSA). It has been shown to have greater specificity and sensitivity than any of its individual components (12). Furthermore, it has been demonstrated to improve the prediction of clinically significant prostate cancer (aggressive histopathology per Epstein criteria or ≥ Gleason 7) in men with a PSA between 4 and 10 ng/ml (13). The use of Phi has the potential to reduce unnecessary biopsies; however, it has not been widely adopted partly due to the pre-analytical stability of [-2]proPSA. For an accurate [-2]proPSA reading, it is recommended that the serum is separated within 3 hours of the sample being taken as the reading increases with clotting time (14).

**Four kallikrein score**

Similar to the Phi test, the 4 Kallikrein (4K) score has also been shown to be a predictor for prostate cancer which can be used to avoid unnecessary biopsies (15,16). It combines four kallikrein markers (total PSA, free PSA, intact PSA and kallikrein-like peptidase 2 [hK2]) with patient age, DRE findings and prior biopsy status. A direct comparison of the 4K score and Phi found both tests to be equally predictive of prostate cancer and clinically significant prostate cancer (17).

**URINE TESTS**

In addition to serum tests, several urinary biomarkers for prostate cancer have been described. These include urinary measurements of prostate cancer gene 3, TMPRSS2:ERG, and SelectMDX test.

**Prostate cancer gene 3**

Prostate cancer gene 3 (PCA3) is a prostate specific non-coding mRNA that is over expressed in prostate cancer and detectable in urine collected after prostatic massage (18). Initial investigations into the use of PCA3 were performed in men with a previous negative biopsy and persistently elevated PSA levels. These early
studies suggested that using a PCA3 cut off score of 35, the test had a sensitivity of 58% and specificity of 72% and was superior to PSA in predicting the biopsy outcome (19–21). However, the ability of the test to predict clinically significant prostate cancers found variable results. Fewer studies have evaluated the use of PCA3 to direct the need for an initial biopsy. One prospective multicenter study in men with a PSA between 2.5 and 10 ng/ml found a sensitivity of 64% and specificity of 76% and similarly found it superior to PSA in predicting biopsy outcome (22). However, further research is still required in the biopsy naïve patient to understand the use of PCA3 in this setting. Consequently, whilst initial research suggests that PCA3 may be useful in predicting the presence of prostate cancer, particularly in patients that have had a previous benign biopsy, it remains unclear whether it can be accurately used to detect clinically significant disease, what cut off levels should be used, and with the extra expense of performing the test, what clinical benefit it truly offers (23).

**TRANSMEMBRANE SERINE PROTEASE 2:ERG**

The *ERG* gene is a transcription factor of the ETS family which has been observed to be overexpressed in prostate cancer as a result of its fusion to the transmembrane protease serine 2 gene (*TMPRSS2*) (24). *TMPRSS2:ERG* fusion transcripts can be detected in urine with a sensitivity of 37% and specificity of 93% (25). Further studies have shown improved diagnostic ability when combined with the PCA3 test (Michigan-Prostate score [MiPS]) (26). However, this is still under investigation and it is likely that the discovery of *TMPRSS2:ERG* will have a bigger role as a potential therapeutic target than for diagnostics.

**SelectMDX test**

Similar to PCA3 and *TMPRSS2:ERG*, the SelectMDX test is based on the presence of mRNA biomarkers in urine namely *HOXC6* and *DLX1*. Combining the presence of these biomarkers with traditional clinical risk factors (PSA, PSA density, DRE, age, history of prostate biopsy and family history), the SelectMDX test has the ability to detect clinically significant prostate cancer (27). Further analysis has demonstrated that the use of SelectMDX may lead to a reduction in unnecessary biopsies and overtreatment (28). However, with the advent of prostate magnetic resonance imaging (MRI), a clear role for all these urinary biomarkers in prostate cancer diagnostics is uncertain. Future research will need to focus on how these biomarkers may be effectively integrated to avoid unnecessary and costly imaging.

**IMAGING**

The role of imaging in prostate cancer diagnostics is rapidly evolving and can be used to identify clinically significant prostate cancers and avoid unnecessary biopsies.
Transrectal ultrasound (TRUS)

Prostate cancer can appear as a hypoechoic lesion on conventional B-mode TRUS; however, this is a non-specific finding. A large prospective study found no significant difference in the detection of prostate cancer from biopsies of patients with or without hypoechoic lesions (25.5% versus 25.4%) (29). This indicates a hypoechoic lesion itself is not associated with an increase in cancer prevalence and B-mode TRUS alone is not diagnostic of prostate cancer. Nevertheless, it serves a vital purpose in identifying the prostate in order to perform biopsies.

Additional variations in ultrasound (US) imaging have also been assessed for their usefulness in diagnosing prostate cancer. Color doppler US (CDUS) measures blood flow and therefore has the potential to detect prostate cancer as a result of increased tumor vasculature. An early evaluation of CDUS found it was able to diagnose up to 70% of prostate cancers but generally performed better in high-grade disease and when used in combination with the conventional B-mode TRUS (30). However, a further study has shown the use of CDUS in targeted prostate biopsies did not improve prostate cancer detection rates when compared with standard TRUS (31). Contrast enhanced US (CEUS) uses microbubble contrast agents to detect increased microvasculature in the prostate. Its use in detecting prostate cancer has been shown to improve the sensitivity when compared to unenhanced CDUS (32). Sonoelastography is based on the principle that there are significant differences in the elastic properties of benign and malignant prostate tissue. The technique estimates the response of tissues under harmonic mechanical excitation using Doppler ultrasound to detect areas of abnormal stiffness (33). The initial study investigating its use found sonoelastography was able to detect 84.1% of prostate cancers (34).

Whilst each of these US techniques has shown promise in initial studies to improve the detection of prostate cancer, combined imaging is reported to offer the most benefit. Multiparametric US (mpUS) consisting of a combination of B-mode, sonoelastography and CEUS improved the sensitivity for clinically significant prostate cancer to 74% from 55%, 55% and 59%, respectively (35). Nevertheless, the use of US in prostate cancer diagnostics is unclear particularly with the recent evolving role of multiparametric-MRI (mp-MRI) which is more accurate than mpUS (36).

Micro-ultrasound is the only US technique that has shown promise in rivalling mp-MRI. Traditional TRUS operates at frequencies of 6–9 MHz whilst micro-ultrasound is a new modality that operates at 29 MHz. This improves image resolution by 300% allowing for the detection of subtle changes in ductal anatomy. Early results of this technique have demonstrated an improvement in the detection of clinically significant prostate cancer and that it may be able to detect lesions missed on multiparametric-MRI (mp-MRI) (37,38). Although further research is required to understand the exact role micro-ultrasound will have in prostate cancer diagnostics.

Multiparametric magnetic resonance imaging

The European Society of Urogenital Radiology recommends mp-MRI for the detection of prostate cancer should include a combination of high-resolution T2 weighted images and at least two functional MRI techniques; diffusion weighted
Prostate cancer typically manifests as a round low signal intensity focus on T2-weighted MRI, high signal intensity on DWI at high b-values and classically demonstrates early enhancement on DCE-MRI. The Prostate Imaging-Reporting and Data System (PI-RADS) provides a structured way to report each lesion by allocating a score between 1 and 5 that predicts its chance of being a clinically significant prostate cancer; with 5 indicating a very high likelihood for the presence of clinically significant prostate cancer (40). A meta-analysis assessing the diagnostic accuracy of mp-MRI for prostate cancer found it to have high specificity and sensitivity, 88% and 74%, with a variable but high negative predictive value ranging from 65–94% (41). Furthermore, a comparison of pre-operative MRI to radical prostatectomy histopathology found prostate cancer detection rates increased with both tumor volume and increasing Gleason score (42). One of the main uses of mp-MRI is to identify a target to biopsy to improve the detection of clinically significant prostate cancers (43). This will be discussed further in the chapter along with its use in staging. In addition, a prebiopsy mp-MRI can also be used to avoid undertaking biopsies in patients with no visible lesions. The PROMIS trial found that using a mp-MRI and only performing a prostate biopsy on patients with PI-RADS lesions of ≥3 could have avoided a biopsy in 27% of patients (44).

**RISK CALCULATORS**

The use of risk calculators can help to combine diagnostic tests to predict an individual patients’ risk of clinically significant prostate cancer and potentially reduce unnecessary investigations. One such validated risk calculator is that developed from the PCPT cohort. The PCPT predictive model was initially developed to combine the patients’ age, race, family history, serum PSA, DRE and prior biopsy status to produce a risk score for having both low- and high-grade prostate cancer on a biopsy (45). Further developments now provide the option to include free PSA, urinary PCA3 and TMPRSS2:ERG into the PCPT calculator (46,47). Other risk calculators also include mp-MRI findings. A systematic review has identified that over 100 prediction models exist in the literature, although not all of these have been validated and currently no single model has shown superiority over another (48).

**PROSTATE BIOPSY**

The modern era of prostate biopsies began with the systematic sextant method in which initially 6 and subsequently 12 ultrasound guided biopsies were taken from 6 sites (apex, middle and base of each lobe) (49). Currently, TRUS guided prostate biopsy can be performed via either a transrectal or transperineal approach. A meta-analysis comparing the two biopsy approaches found the diagnostic accuracy to be comparable, however, the transperineal approach was associated with a lower risk of fever and rectal bleeding (50). Following the publication of the landmark PROMIS study, a prebiopsy mp-MRI is now the gold standard to perform
targeted biopsies (44). A subsequent Cochrane review found this approach increases the number of significant cancers detected while reducing the number of insignificant cancers diagnosed (43). Different methods for performing targeted biopsies of lesions identified on mp-MRI exist; direct in-bore targeted biopsy, fusion biopsy, and cognitive targeted biopsy.

Direct in-bore targeted biopsy

Direct in-bore MRI targeted biopsy in which the biopsies are performed in the MR scanner using real time MRI guidance. A prospective matched cohort study comparing this technique with a 10-core TRUS biopsy found a significantly improved correlation with histology at radical prostatectomy (88% versus 55%) (51). However, this is a labor intense and costly procedure, taking up 2–3 hours of scanning time. It requires administration of a general anesthetic with the patient in the scanner potentially creating difficulty with airway management.

MRI fusion biopsy

An MRI-transperineal or transrectal fusion target biopsy is where software is used to merge the MRI image of the prostate with the TRUS image in real time to accurately direct biopsies. Several different systems are available including Artemis, Biopsee and Koelis Trinity. The system records the site of biopsy confirming that the selected target has been sampled and is useful for future reference. This approach takes some extra time as the prostate and lesion requires contouring but is faster and less expensive than the direct in-bore biopsy technique. The main potential source of error is in the co-registration of the MRI and TRUS images. The prostate images are obtained in different positions; MRI in supine and TRUS either in the left lateral or lithotomy with the hips flexed which rotates the prostate within the pelvis. Image registration is either rigid or elastic. Rigid image registration overlays the MRI images onto the TRUS images without any adjustment for possible deformation during the procedure such as from patient movement. Whilst elastic registration does compensate for this deformation and, therefore, would be anticipated to be more accurate. However, a meta-analysis comparing rigid and elastic registration found no significant difference in the detection of clinically significant prostate cancer (52).

Cognitive targeted biopsy

Finally, cognitive targeted biopsy or visual registration are where the MRI images are reviewed by the urologist who then performs the biopsies, either via a transperineal or transrectal route, using TRUS guidance aiming to sample the general location of the suspicious lesion. This is the simplest, fastest, and cheapest method to perform MRI-targeted biopsies. However, the accuracy is highly dependent on operator experience and training requiring good knowledge of prostate zonal anatomy on both MRI and TRUS images. Furthermore, in cases of negative template biopsy for quality control there is no ability to check whether the target was sampled (53). Despite this, a comparison of cognitive targeted to systematic biopsies found no statistically significant difference in the detection
of clinically significant prostate cancer and found fewer insignificant cancers were detected (54).

**What is the preferred biopsy approach?**

There is clear evidence that MRI targeted biopsies improve the detection of clinically significant prostate cancer and results in fewer insignificant lesions being detected. So far studies have failed to demonstrate any of the different MRI targeting techniques described to be superior to another (55, 56). Targeted biopsies can be taken via a transperineal or transrectal approach with the former having a reduced risk of sepsis (50). Other factors to consider when performing a biopsy include anesthetic and position. Biopsies can be performed under general or local anesthetic. The local anesthetic technique has been shown to have good patient tolerability without the associated risks of a general anesthetic and with reduced operative time and patient recovery (57). Furthermore, biopsies under local anesthetic can be performed in the lithotomy or left lateral decubitus position, with the latter associated with improved pain scores (58).

**STAGING**

Once a diagnosis of prostate cancer has been reached, the patient requires clinical staging in order to direct the appropriate treatment.

**Multiparametric magnetic resonance imaging**

In addition to directing the need for a prostate biopsy, mp-MRI can be used for local staging of prostate cancer. T2-weighted imaging can be used to look for extracapsular extension (ECE) (T3a), seminal vesicle invasion (SVI) (T3b) and invasion into other organs (T4). Pooled data from a meta-analysis has demonstrated mp-MRI has high specificity but poor sensitivity in detecting ECE, 91% and 57%, and SVI, 96% and 58%, respectively (59). The use of mp-MRI to assess the prostate for suspicious lesions also indirectly provides an assessment of nodal disease. However, similar to its use in local staging, mp-MRI has also been shown to have poor sensitivity for the detection of nodal disease. A meta-analysis found a pooled sensitivity of 39% and specificity of 82% with significant study heterogeneity (60). Accordingly, mp-MRI can therefore not be completely relied upon for local staging for the presence of lymph node metastases.

**Computed tomography**

The use of computed tomography (CT) in the detection of lymph node metastases has also been shown to be an unreliable method. Similar to mp-MRI, a meta-analysis found a good specificity at 82% but a poor sensitivity of 42% (60). The main drawback in the use of CT and mp-MRI to detect lymph node metastases is their reliance on nodal enlargement which is not always present (61).
Choline positron emission tomography CT

The use of choline positron emission tomography (PET) CT is based on high uptake of the radiotracer believed to be due to the increase in membrane phosphatidylcholine in cancer cells (62). Its use in prostate cancer diagnostics has largely been evaluated in its ability to detect lymph node metastases which has found variable results. However, its utilization in high-risk prostate cancer has demonstrated a significantly improved specificity and sensitivity suggesting it may be useful under these conditions for the detection of nodal metastases (63). Although, with the developments in $^{68}$Gallium ($^{68}$Ga) labelled prostate specific membrane antigen (PSMA) PET-CT, it is unclear whether choline PET-CT will have a role in the future of prostate cancer diagnostics.

Bone scan

Bone metastases are most frequently looked for using a technetium Tc 99m methylene disphophonate ($^{99}$m Tc MDP) bone scan. PSA, Gleason score, and clinical stage are all significant predictors of bone metastases. It is suggested that a staging baseline bone scan should be performed in patients with intermediate (PSA 10–20 ng/ml or Gleason score 7 or cT2b) or high-risk prostate cancer (PSA >20ng/ml or Gleason score 8–10 or cT2c/3/4). By using these criteria, it was found that staging baseline bone scan could be avoided in approximately 81% of patients with a negative predictive value of 99.6% (64).

Prostate specific membrane antigen-based PET CT

$^{68}$Ga PSMA PET-CT shows great promise in improving prostate cancer diagnostics. PSMA is over-expressed on the cell membrane of nearly all prostate cancer cells with expression levels increasing according to the stage and grade of tumor (65). A meta-analysis comparing $^{68}$Ga PSMA PET CT with MRI for the diagnosis of lymph node metastases in patients with intermediate or high-risk prostate cancer found $^{68}$Ga PSMA PET CT to have a higher sensitivity (65% versus 41%) (66). A further meta-analysis has also demonstrated $^{68}$Ga PSMA PET-CT to have the highest sensitivity and specificity for the diagnosis of bone metastases when compared with choline PET-CT, MRI, and bone scintigraphy (67). A recent multicenter randomized study also found $^{68}$Ga PSMA PET-CT in men with high-risk prostate cancer (Gleason grade group 3–5, PSA ≥20 or clinical stage ≥T3) was superior to bone scan and CT, with a 92% accuracy. Importantly, this improved method of staging resulted in more frequent changes to the patients’ management plan, and it therefore has the potential to offer the most appropriate first line therapy in addition to avoiding unnecessary treatment (68).

CONCLUSION

The integration of these diagnostic tools for prostate cancer enables the urologist to risk stratify patients and appropriately direct the diagnostic path. There have been significant improvements in the detection of clinically significant prostate
cancer in addition to preventing overdiagnosis as well as improvements in staging. However, further advances to improve the sensitivity of staging investigations and streamlining of the pathway are required to make this both clinically and cost-effective.

Conflict of interest: The authors declare no potential conflict of interest with respect to research, authorship and/or publication of this chapter.

Copyright and permission statement: The authors confirm that the materials included in this chapter do not violate copyright laws. Where relevant, appropriate permissions have been obtained from the original copyright holder(s), and all original sources have been appropriately acknowledged or referenced.

REFERENCES

1. Gosselaar C, Kranse R, Roobol MJ, Roemeling S, Schroder FH. The interobserver variability of digital rectal examination in a large randomized trial for the screening of prostate cancer. Prostate. 2008; 68(9): 985–93. https://doi.org/10.1002/pros.20759
2. Richie JP, Catalona WJ, Ahmann FR, Hudson MA, Scardino PT, Flanigan RC et al. Effect of patient age on early detection of prostate cancer with serum prostate-specific antigen and digital rectal examination. Urology. 1993; 42(4): 365–74. https://doi.org/10.1016/0090-4295(93)90359-I
3. Thompson IM, Paulell DK, Goodman PJ, Tangen CM, Scott Lucia M, Parnes HL et al. Prevalence of prostate cancer among men with a prostate-specific antigen level < or = 4.0 ng per millilitre. N Engl J Med. 2004; 350(22): 2239–46. https://doi.org/10.1056/NEJMoa031918
4. Eastham JA, Riedel E, Scardino PT, Shike M, Fleisher M, Schatzkin A et al. Variation of serum prostate specific antigen levels. JAMA. 2003; 289(20): 2695–700. https://doi.org/10.1001/jama.289.20.2695
5. Oesterling JE, Jacobsen SJ, Chute CG, Guess HA, Girman CJ, Panser LA et al. Serum prostate-specific antigen in a community-based population of healthy men. Establishment of age-specific reference ranges. JAMA. 1993; 270(7): 860–4. https://doi.org/10.1001/jama.1993.03510070082041
6. Benson MC, Olsson CA. Prostate specific antigen and prostate specific antigen density. Roles in patient evaluation and management. Cancer. 1994; 74(6): 1667–73. https://doi.org/10.1002/1097-0142(19940915)74:6<1667::AID-CNCR2820740605>3.0.CO;2-2
7. Jue JS, Barboza MP, Prakash NS, Venkatramani V, Sinha VR, Pavan N et al. Re-examining prostate-specific antigen (PSA) density: defining the optimal PSA range and patients for using PSA density to predict prostate cancer using extended template biopsy. Oncology. 2017; 105: 123–8. https://doi.org/10.1016/j.onco.2017.04.015
8. Vickers AJ, Brewster SF. PSA Velocity and Doubling Time in Diagnosis and Prognosis of Prostate Cancer. Br J Med Surg Urol. 2012; 5(4): 162–8. https://doi.org/10.1016/j.bjmsu.2011.08.006
9. Catalona WJ, Smith DS, Wolfert RL, Wang TJ, Rittenhouse HG, Ratliff TL, et al. Evaluation of percentage of free serum prostate-specific antigen to improve specificity of prostate cancer screening. JAMA. 1995; 274(15): 1214–20. https://doi.org/10.1001/jama.1995.03530150383011
10. Catalona WJ, Partin AW, Slawin KM, Brawer MK, Flanigan RC, Patel A et al. Use of the percentage of free prostate-specific antigen to enhance differentiation of prostate cancer from benign prostatic disease. JAMA. 1998; 279(19): 1542–7. https://doi.org/10.1001/jama.1998.279.19.1542
11. Stephan C, Lein M, Jung K, Schnorr D, Loening SA. The influence of prostate volume on the ratio of free to total prostate specific antigen in serum of patients with prostate carcinoma and benign prostate hyperplasia. Cancer. 1997; 79(1): 104–9. https://doi.org/10.1002/(SICI)1097-0142(19970101)79:1<104::AID-CNCR15>3.0.CO;2-8
12. Catalona WJ, Partin AW, Sanda MG, Wei JT, Klee GG, Bangma CH et al. A multicentre study of [-2] pro-prostate specific antigen combined with prostate specific antigen and free prostate specific
antigen for prostate cancer detection in the 2.0 to 10.0ng/ml prostate specific antigen range. J Urol. 2011; 185(5): 1650–5. https://doi.org/10.1016/j.juro.2010.12.032

13. Loeb S, Sanda MG, Broyles DL, Shin SS, Bangma CH, Wei JT et al. The prostate health index selectively identifies clinically significant prostate cancer. J Urol. 2015; 193(4): 1163–9. https://doi.org/10.1016/j.juro.2014.10.121

14. Semjonow A, Kopke T, Eltze E, Pepping-Schefers B, Bürgel H, Darte C. Pre-analytical in-vitro stability of [-2]proPSA in blood and serum. Clin Biochem. 2010; 43(10–11): 926–8. https://doi.org/10.1016/j.clinbiochem.2010.04.062

15. Vickers AJ, Cronin AM, Aus G, Pihl C, Becker C, Pettersson K et al. A panel of kallikrein markers can reduce unnecessary biopsy for prostate cancer: data from the European Randomized study of prostate cancer screening in Goteborg, Sweden. BMC Med. 2008; 6: 19. https://doi.org/10.1186/1741-7015-6-19

16. Parekh DJ, Punnen S, Sjoberg DD, Asroff SW, Bailen JL, Cochran JS et al. A multi-institutional prospective trial in the USA confirms that the 4Kscore accurately identifies men with high-grade prostate cancer. Eur Urol. 2015; 68(3): 464–70. https://doi.org/10.1016/j.euro.2014.10.021

17. Nordström T, Vickers A, Assel M, Lilja H, Gronberg H, Eklund M. Comparison between the four-kallikrein panel and prostate health index for predicting prostate cancer. Eur Urol. 2015; 68(1): 139–46. https://doi.org/10.1016/j.euro.2014.08.010

18. Hesse D, Gunnewiek JM, Oort IV, Karthaus HFM, van Leenders GJL, Balken BV et al. DD3-PCA3-based molecular urine analysis for the diagnosis of prostate cancer. Eur Urol. 2003 Jul; 44(1): 8–16. https://doi.org/10.1016/S0302-2838(03)/00201-X

19. Marks LS, Fradet Y, Deras IL, Blase A, Mathis J, Aubin SMJ et al. PCA3 molecular urine assay for prostate cancer in men undergoing repeat biopsy. Urology. 2007; 69(3): 532–5. https://doi.org/10.1016/j.urology.2006.12.014

20. Deras IL, Aubin SMJ, Blase A, Day JR, Koo S, Partin AW et al. PCA3: A molecular urine assay for predicting prostate biopsy outcome. J Urol. 2008; 179(4): 1587–92. https://doi.org/10.1016/j.juro.2007.11.038

21. Haeze A, de la Taille A, van Poppel H, Marberger M, Stenzl A, Mulders PFA et al. Clinical utility of the PCA3 urine assay in European men scheduled for repeat biopsy. Eur Urol. 2008; 54(5): 1081–8. https://doi.org/10.1016/j.euro.2008.06.071

22. De la Taille A, Irani J, Graefen M, Chun F, de Reijke T, Kil P et al. Clinical evaluation of the PCA3 assay in guiding initial biopsy decisions. J Urol. 2011; 185(6): 2119–25. https://doi.org/10.1016/j.juro.2011.01.075

23. Nicholson A, Mahon J, Boland A, Beale S, Dwan K, Fleeman N et al. The clinical effectiveness and cost-effectiveness of the PROGENSA® prostate cancer antigen 3 assay and the Prostate Health Index in the diagnosis of prostate cancer: a systematic review and economic evaluation. Health Technol Assess. 2015; 19(87): ii–xxxi, 1–191. https://doi.org/10.3310/hta19870

24. Tomlins SA, Mehr R, Rhodes DR, Smith L, Roulston D, Helgeson BE et al. TMPRSS2-ETV4 gene fusions define a third molecular subtype of prostate cancer. Cancer Res. 2006; 66(7): 3396–400. https://doi.org/10.1158/0008-5472.CAN-06-0168

25. Hesse D, Smitt FP, Verhaegh GW, Witjes JA, Corel EB, Schalken JA. Detection of TMPRSS2-ERG fusion transcripts and prostate cancer antigen 3 in urinary sediments may improve diagnosis of prostate cancer. Clin Cancer Res. 2007; 13(17): 5103–8. https://doi.org/10.1158/1078-0432.CCR-07-0700

26. Tomlins SA, Day JR, Lonigro RJ, Hovelson DH, Siddiqui J, Kunju LP et al. Urine TMPRSS2:ERG plus PCA3 for individualized prostate cancer risk assessment. Eur Urol. 2016; 70(1): 45–53. https://doi.org/10.1016/j.eururo.2015.04.039

27. Van Neste L, Hendriks RJ, Dijkstra S, Trooskens G, Cornel EB, Jannink SA et al. Detection of high-grade prostate cancer using a urinary molecular biomarker-based risk score. Eur Urol. 2016; 70(5): 740–8. https://doi.org/10.1016/j.eururo.2016.04.012

28. Dijkstra S, Govers TM, Hendriks RJ, Schalken JA, Crikinge WV, Van Neste L et al. Cost-effectiveness of a new urinary biomarker-based risk score compared to standard of care in prostate cancer diagnostics - a decision analytical model. BJU Int. 2017; 120(5): 659–65. https://doi.org/10.1111/bju.13861
29. Onur R, Littrup PJ, Pontes JE, Bianco FJ. Contemporary impact of transrectal ultrasound lesions for prostate cancer detection. J Urol. 2004; 172(2): 512–4. https://doi.org/10.1097/01.ju.0000131621.61732.6b

30. Shigeno K, Igawa M, Shina H, Wada H, Yoneda T. The role of colour Doppler ultrasonography in detecting prostate cancer. BJU Int. 2000; 86: 229–33. https://doi.org/10.1046/j.1464-410x.2000.00829.x

31. Taverna G, Morandi G, Seveso M, Giusti G, Benetti A, Colombo P, et al. Colour Doppler and microbubble contrast agent ultrasonography do not improve cancer detection rate in transrectal systematic prostate biopsy sampling. BJU Int. 2011; 108(11): 1723–7. https://doi.org/10.1111/j.1464-410x.2011.10199.x

32. Roy C, Buy X, Lang H, Saussine C, Jacqmin D. Contrast enhanced color doppler endorectal sonography of prostate: efficiency for detecting peripheral zone tumors and role for biopsy procedure. J Urol. 2003; 170(1): 69–72. https://doi.org/10.1097/01.ju.0000072342.01573.8d

33. Hoyt K, Castaneda B, Zhang M, Nigwekar P, di Sant’Agnese PA, Joseph JV et al. Tissue elasticity properties as biomarkers for prostate cancer. Cancer Biomark. 2008; 4(4–5): 213–25. https://doi.org/10.3233/CBM-2008-44-505

34. König K, Schepers U, Pesavento A, Lorenz A, Ermert H, Senge T. Initial experiences with real-time elastography guided biopsies of the prostate. 2005; 174(1): 1166–73. https://doi.org/10.1016/j.ju.0000162043.72294.4a

35. Mannaerts CK, Wildeboer RR, Remmers S, van Kollenburg RAA, Kajtazovic A, Hagemann J, et al. Multiparametric ultrasound for prostate cancer detection and localization: correlation of B-mode, shear wave elastography and contrast enhanced ultrasound with radical prostatectomy specimens. J Urol. 2019; 202(6): 1341–54. https://doi.org/10.1016/j.jultrasoundmedbio.2018.02.014

36. Bratan F, Niaf E, Melodelima C, Chesnais AL, Souchon R, Mège-Lechevallier F, et al. Influence of imaging and histological factors on prostate cancer detection and localisation on multiparametric MRI: a prospective study. Eur Radiol. 2013; 23(7): 2019–29. https://doi.org/10.1007/s00330-011-2377-y

37. Drost FJH, Osses DF, Nieboer D, Steyerberg EW, Bangma CH, Roobol MJ, et al. Prostate MRI, with or without MRI-targeted biopsy, and systematic biopsy for detecting prostate cancer. Cochrane Database Syst Rev. 2019; 4(4): CD012663. https://doi.org/10.1002/14651858.CD012663.pub2

38. Ahmed HU, Bosaify AE, Brown LC, Gabe R, Kaplan R, Parmar MK, et al. Diagnostic accuracy of multiparametric MRI and TRUS biopsy in prostate cancer (PROMIS): a paired validating confirmatory study. Lancet. 2017; 389(10071): 815–22. https://doi.org/10.1016/S0140-6736(16)32401-1

39. Thompson IM, Ankerst DP, Chi C, Goodman PJ, Tangen CM, Lucia MS et al. Assessing prostate cancer risk: results from the Prostate Cancer Prevention Trial. J Natl Cancer Inst. 2006; 98(8): 529–34. https://doi.org/10.1093/jnci/dji131

40. Ankerst DP, Hoefler J, Bock S, Goodman PJ, Vickers A, Hernandez J et al. Prostate Cancer Prevention Trial risk calculator 2.0 for the prediction of low- vs high-grade prostate cancer. Urology. 2014; 83(6): 1362–7. https://doi.org/10.1016/j.urology.2014.02.035
47. Ankerst DP, Goros M, Tomlins SA, Patil D, Fennig Z, Wei JT et al. Incorporation of urinary prostate cancer antigen 3 and TMPRSS2:ERG into Prostate Cancer Prevention Trial Risk Calculator. Eur Urol Foc. 2019; 5(1): 54–61. https://doi.org/10.1016/j.euf.2018.01.010

48. Louie KS, Seigneurin A, Cathcart P, Sasieni P. Do prostate cancer risk models improve the predictive accuracy of PSA screening? A meta-analysis. Ann Oncol. 2015; 26(5): 848–64. https://doi.org/10.1093/annonc/mdu525

49. Hodge KK, McNeal JE, Terris MK, Stamey TA. Random systematic versus directed ultrasound guided transrectal core biopsies of the prostate. J Urol. 1989; 142(1): 71–4. https://doi.org/10.1016/S0022-5347(17)38664-0

50. Xiang J, Yan H, Li J, Wang X, Chen H, Zheng X. Transperineal versus transrectal prostate biopsy in the diagnosis of prostate cancer: a systematic review and meta-analysis. World J Surg Oncol. 2019; 17(1): 31. https://doi.org/10.1186/s12957-019-1573-0

51. Hambrock T, Hoeks C, Hulsbergen-van de Kaa C, Scheenen T, Fütterer J, Bouwense S, et al. Prospective assessment of prostate cancer aggressiveness using 3-T diffusion-weighted magnetic resonance imaging-guided biopsies versus a systematic 10-core transrectal ultrasound prostate biopsy cohort. Eur Urol. 2012; 61(1): 177–84. https://doi.org/10.1016/j.euro.2011.08.042

52. Venderink W, de Rooij M, Sedelaar JPM, Juismen JH, Fütterer HJ. Elastic versus rigid image registration in magnetic resonance imaging-transrectal ultrasound fusion prostate biopsy: a systematic review and meta-analysis. Eur Urol. 2018; 4(2): 219–27. https://doi.org/10.1016/j.euf.2016.07.003

53. Puech P, Ouzzane A, Gaillard V, Betouni N, Renard B, Villers A, et al. Multiparametric MRI-targeted TRUS prostate biopsies using visual registration. Biomed Res Int. 2014; 819360 https://doi.org/10.1155/2014/819360

54. Kasivisvanathan V, Dufour R, Moore CM, Ahmed HU, Abd-Alazeez M, Charman SC, et al. Transperineal magnetic resonance image targeted prostate biopsy versus transperineal template prostate biopsy in the detection of clinically significant prostate cancer. J Urol. 2013; 189(3): 860–6. https://doi.org/10.1016/j.juro.2012.10.009

55. Wegelin O, van Melick HHE, Hooft L, Ruud Bosch JH, Reitsma HB, Barentsz JO, et al. Comparing three different techniques for magnetic resonance imaging-targeted prostate biopsies: A systematic review of in-bore versus magnetic resonance imaging-transrectal ultrasound fusion versus cognitive registration. Is there a preferred technique? Eur Urol. 2017; 71(4): 517–31. https://doi.org/10.1016/j.euro.2016.07.041

56. Wegelin O, Exterkate L, van der Leest M, Kummer JA, Vreuls W, de Bruin PC et al. The FUTURE Trial: a multicentre randomised controlled trial on target biopsy techniques based on magnetic resonance imaging in the diagnosis of prostate cancer in patients with prior negative biopsies. Eur Urol. 2019; 75(4): 582–90. https://doi.org/10.1016/j.euro.2018.11.040

57. Stefanova V, Buckely, Flax S, Spevack L, Hajek D, Tunis A, et al. Transperineal prostate biopsies using local anesthesia: experience with 1,287 patients. Prostate cancer detection rate, complications and patient tolerability. J Urol. 2019; 201(6): 1121–6. https://doi.org/10.1097/JU.0000000000001516

58. Lodeta B, Lodeta M. Prostate biopsy in the left lateral decubitus position is less painful than prostate biopsy in the lithotomy position: a randomized controlled trial. Korean J Urol. 2012; 53(2): 87–91. https://doi.org/10.4111/kju.2012.53.2.87

59. De Rooij M, Hamoen EHJ, Witjes JA, Barentsz JO, Rovers MM. Accuracy of magnetic resonance imaging for local staging of prostate cancer: a diagnostic meta-analysis. Eur Urol. 2016; 70(2): 233–45. https://doi.org/10.1016/j.euro.2015.07.029

60. Hovels AM, Heesakkers RAM, Adang EM, Jager GJ, Strum S, Hoogeveen YL, et al. The diagnostic accuracy of CT and MRI in the staging of pelvic lymph nodes in patients with prostate cancer: a meta-analysis. Clin Radiol. 2008; 63(4): 387–95. https://doi.org/10.1016/j.crad.2007.05.022

61. Tiguert R, Cheiler EL, Tefilli MV, Oskanian P, Banerjee M, Grignon DJ, et al. Lymph node size does not correlate with the presence of prostate cancer metastasis. Urology. 1999; 53(2): 367–71. https://doi.org/10.1016/S0090-4295(98)00518-4

62. Schwarenböck S, Souvatzoglou M, Krause BJ. Choline PET and PET/CT in primary diagnosis and staging of prostate cancer. Theranostics. 2012; 2(3): 318–30. https://doi.org/10.7150/thno.4008
63. Schiavina R, Bianchi L, Bianchii FM, Borghesi M, Pultrone CV, Dababneh H et al. Preoperative staging with 11C-Choline PET/CT is adequately accurate in patients with very high-risk prostate cancer. Clin Genitourin Cancer. 2018; 16(4): 305–12. https://doi.org/10.1016/j.clgc.2018.05.010

64. Briganti A, Passoni N, Ferrari M, Capitanio U, Suardi N, Gallina A, et al. When to perform bone scan in patients with newly diagnosed prostate cancer: external validation of the currently available guidelines and proposal of a novel risk stratification tool. Eur Urol. 2010; 57(4): 551–8. https://doi.org/10.1016/j.eururo.2009.12.023

65. Maurer T, Elber M, Schwaiger M, Gschwend JE. Current use of PSMA-PET in prostate cancer management. Nat Rev Urol. 2016; 13(4): 226–35. https://doi.org/10.1038/nrurol.2016.26

66. Wu H, Xu T, Wang X, Yu YB, Fan ZY, Li DX et al. Diagnostic Performance of 68Gallium labelled prostate-specific membrane antigen positron emission tomography/computed tomography and magnetic resonance imaging for staging the prostate cancer with intermediate or high risk prior to radical prostatectomy: a systematic review and meta-analysis. World J Mens Health. 2020; 38(2): 208–19. https://doi.org/10.5534/wjmh.180124

67. Zhou J, Gou Z, Wu R, Yuan Y, Yu G, Zhao Y. Comparison of PSMA-PET/CT, choline PET/CT, NaF-PET/CT, MRI, and bone scintigraphy in the diagnosis of bone metastases in patients with prostate cancer: a systematic review and meta-analysis. Skeletal Radiol. 2019; 48(12): 1915–24. https://doi.org/10.1007/s00256-019-03230-z

68. Hofman MS, Lawrentschuk N, Francis RJ, Tang C, Vela I, Thomas P et al. Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA): a prospective, randomised, multicentre study. Lancet. 2020; 395(10231): 1208–16. https://doi.org/10.1016/S0140-6736(20)30314-7
